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CC BY-NC-ND license (http://creativeAbstract Duchenne muscular dystrophy (DMD) is a progressive muscle degenerative disease
affecting one out of 3500 male births. Patients usually succumb to the disease by age 25. It
has been shown that skipping exons of the DMD gene that contain disease-causing mutations
from the pre-mRNA can result in a shortened, but functional, dystrophin protein that could
bring clinical benefits to patients. A recent breakthrough has been reported in Science by three
groups who demonstrated that genetically deleting exon 23 by gene editing can restore the
expression of dystrophin (albeit a shortened version) and improve the muscle function in a
mouse model of DMD.
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fatal genetic disease that results in muscle degeneration, a
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commons.org/licenses/by-nc-nd/cure for the disease. The DMD gene is located on the X
chromosome and is the largest known human gene. DMD
contains 79 exons and encodes a protein, dystrophin, which
is crucial for sarcolemmal integrity. The disease-causing
mutations include deletions (present in about 72% of pa-
tients) and partial duplications (in about 7% of patients) or
point mutations (in about 20% of patients).1 Some of the
mutation-containing exons can be removed, which results
in a truncated, but functional gene product with thera-
peutic effects. For example, removal of exon 51 would be
useful to treat 13% of DMD patients. Indeed, it has beenand hosting by Elsevier B.V. This is an open access article under the
4.0/).
102 J. Hu et al.shown that intramuscular injection of an antisense oligo-
nucleotide induced dystrophin synthesis in four patients
with Duchenne muscular dystrophy who had suitable mu-
tations.1 Although this approach could bring benefits to
patients, it is not a permanent solution, because it miti-
gates genetic defects at the RNA level and requires life-long
administration of the antisense oligonucleotides.
Recently, three research articles published in Science
have described a potentially permanent solution to the
problem.2e4 Using a mouse model of human DMD, the au-
thors have shown that deleting exon 23 of the DMD gene in
mice using a gene editing approach could partially restore
the dystrophin function in skeletal myofibers and cardiac
muscle, leading to significant improvements in muscle
function and biochemistry. This was accomplished by using
adeno-associated virus serotype 8 or 9 (AAV8 or AAV9) to
deliver the clustered regularly interspaced short palin-
dromic repeats (CRISPR) and the CRISPR associated genes 9
(Cas9)-system to the mice. Two AAV vectors were used, one
to deliver the CRISPR-Cas9 enzyme and the other to deliver
two guide RNAs specifically targeting the regions flanking
exon 23. Since both AAV8 and AAV9 can be used for systemic
delivery, both local intramuscular and systemic delivery
routes were tested and were found to be able to partially
restore the dystrophin expression and muscle function.
This is an excellent example of a case where the CRISPR-
Cas9 system can be used, because removal of an exon does
not require homologous recombination, and imprecise
deletion of a few nucleotides through non-homologous end
joining can be tolerated. In fact, more than half of the
dystrophin mutations are suitable candidates for custom-
designed gene editing to remove mutated exons. The
correction of point mutations is also feasible, but remains
technically challenging. The efficiency of this approach is
expected to be enhanced if a single AAV vector could
deliver both the CRISPR-Cas9 and the guide RNAs. Before
the application of this approach in patients, the host im-
mune responses to CRISPR-Cas9 need to be tested in large
animals. It is already known that the AAV vector and
transgene expression can persist for a long time in trans-
duced cells. While continuous expression of the Cas9system could gradually increase the percentage of cellular
DNA to be corrected, it is also associated with the risk of
accumulating off-target DNA excisions, and hence, muta-
tions. Improvements are being made that can lead to the
development of transient and inducible CRISPR systems of
high precision. Taken together, these studies provide a
proof-of-principle that gene editing may be useful to treat
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